Asset profile
HS-20094
Peptide
Evidence outlook · lead readout
NCT06839664 · Overweight, Obesity
The completed lead evidence has the design features that historically survive confirmatory trials: randomized, controlled, and adequately powered against a prespecified clinically accepted endpoint.
NCT06839664: This was a randomized, double-blind, placebo-controlled trial (n=604). The co-primary endpoints, percent weight change and the proportion achieving at least 5% weight loss at week 48, were both met: participants lost up to 19.3% of body weight and up to 97.2% achieved at least 5% weight loss, both significantly better than placebo.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
72 competitors in this universe: 11 direct rivals (same mechanism and indication), 1 same-class, 60 same-indication; 8 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| HS-20094: this drug | Phase 3 | Peptide | GLP-1/GIP receptor (dual) | ||
| Tirzepatide (Zepbound / Mounjaro) | Approved | Peptide | GLP-1/GIP receptor (dual) | ||
| BGM0504 | Phase 3 | Peptide | GLP-1/GIP receptor (dual) | ||
| Brenipatide | Phase 3 | Peptide | GLP-1/GIP receptor (dual) | ||
| Enicepatide | Phase 3 | Peptide | GLP-1 receptor, GLP-1/GIP receptor (dual) | ||
| HDM1005 | Phase 3 | Peptide | GLP-1/GIP receptor (dual) | ||
| RAY1225 | Phase 3 | Peptide | GLP-1/GIP receptor (dual) | ||
| Ribupatide | Phase 3 | Peptide | GLP-1/GIP receptor (dual) | ||
| VK2735 | Phase 3 | Peptide | GLP-1/GIP receptor (dual) | ||
| NNC0519-0130 | Phase 2 | Peptide | GLP-1/GIP receptor (dual) | ||
| Olatorepatide | Phase 2 | Peptide | GLP-1/GIP receptor (dual) | ||
| THDBH120 | Phase 2 | Peptide | GLP-1/GIP receptor (dual) | ||
| KP405 | Phase 1 | Peptide | GLP-1/GIP receptor (dual) | ||
| Liraglutide (Saxenda / Victoza) | Approved | Peptide | GLP-1 receptor | ||
| Naltrexone / Bupropion (Contrave) | Approved | Small molecule | Opioid receptor / dopamine (combination) | ||
| Orforglipron (Foundayo) | Approved | Small molecule | GLP-1 receptor |
…and 57 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
5 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(4 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (1)
November 2026 (1)
What to watch
2027 (2)
2028 (1)
January 2028 (1)
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.